Based on the results of this trial together with evidence from the adequate and well controlled Phase 3 study in pediatric patients aged 5 years and older Study 111 301 safety and effectiveness of VOXZOGO have been established in pediatric patients of all ages for the improvement in linear growth in children with achondroplasia with open epiphyses